Evidence map›Paper›PMID 38045332›Full record

ArticleResearch square2023

Progressive degeneration in a new

Alyson L Sujkowski, Bedri Ranxhi, Matthew V Prifti, Nadir Alam, Sokol V Todi, Wei-Ling Tsou

Open access · greenAbstract readPreprint
In one paragraph

Article in Research square, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Alyson L SujkowskiDepartment of Pharmacology, Wayne State University School of Medicine.
Bedri RanxhiDepartment of Pharmacology, Wayne State University School of Medicine.
Matthew V PriftiDepartment of Pharmacology, Wayne State University School of Medicine.
Nadir AlamDepartment of Pharmacology, Wayne State University School of Medicine.
Sokol V TodiDepartment of Pharmacology, Wayne State University School of Medicine.
Wei-Ling TsouDepartment of Pharmacology, Wayne State University School of Medicine.
Wayne State University · US

Funding

Protection against Alzheimer's Disease proteins by novel ubiquitin processesR01NS086778 · NINDS · WAYNE STATE UNIVERSITY · PI Sokol Todi · 2014 to 2026
$4.9M
NINDS NIH HHS R01 NS086778
6 · The paper itself

Abstract

Spinocerebellar ataxia type 7 (SCA7) is a progressive neurodegenerative disorder resulting from abnormal expansion of polyglutamine (polyQ) in its disease protein, ataxin-7 (ATXN7). ATXN7 is part of Spt-Ada-Gcn5 acetyltransferase (SAGA), an evolutionarily conserved transcriptional coactivation complex with critical roles in chromatin remodeling, cell signaling, neurodifferentiation, mitochondrial health and autophagy. SCA7 is dominantly inherited and characterized by genetic anticipation and high repeat-length instability. Patients with SCA7 experience progressive ataxia, atrophy, spasticity, and blindness. There is currently no cure for SCA7, and therapies are aimed at alleviating symptoms to increase quality of life. Here, we report novel

Indexed as

AggregationPolyglutamineProteinopathyRetinal degeneration

Identifiers

PMID38045332
PMCPMC10690306
OpenAlexW4388923905

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.